Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

LABORATÓRIOS PFIZER LDA

NIF 500162166
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €56,458,056 135 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €56,458,056 135 contracts
A2 · Late Publication €29,829,874,558 6,772 contracts
Contract published to BASE more than 10 days after the signing date
LOW €29,829,874,558 6,772 contracts
A5 · Threshold Splitting €18,823,819 222 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €18,823,819 222 contracts
A6 · Low Competition €6,773,045 73 contracts
Only one bidder participated in a competitive procedure
MEDIUM €6,773,045 73 contracts
A9 · Price Overrun €21,333 5 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €21,333 5 contracts
A9 · Abnormal Price Reduction €36,629,926,533 3,688 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €36,629,926,533 3,688 contracts
B5 · Benford's Law Deviation €983,875,478 4 contracts
Entity's contract values deviate from the Benford leading-digit distribution (chi-square goodness-of-fit, min 20 contracts). Score: 35 (p<0.05) or 55 (p<0.01).
MEDIUM €983,875,478 4 contracts
C3 · Missing Mandatory Fields €15,847,744 196 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €15,847,744 196 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

886
€4,993,899,452
624
€1,263,106,038
209
€1,227,738,395
212
€1,216,896,438
1,072
€1,149,909,681
143
€1,075,187,477
222
€1,072,329,340
73
€1,055,805,117
90
€1,047,815,411
291
€1,044,515,760
130
€1,043,365,206
80
€1,042,745,652
100
€1,034,016,470
62
€1,022,876,502
39
€1,012,980,395
387
€1,012,502,146
97
€997,109,581
507
€949,915,644
223
€926,252,911
310
€923,744,593
Page 1 of 5 · 81 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction B5 · Benford's Law Deviation C3 · Missing Mandatory Fields

Page 1 of 2 · 73 contracts

2025002016 – Aquisição de medicamentos
PT · 11307541 · Ajuste Direto Regime G...
A6 · Low Competition
€10,043 2025-03-26
Ajuste direto para aquisição de E471, E451, E473, R147 e R148 doentes em tratamento
PT · 11298343 · Ajuste Direto Regime G...
A6 · Low Competition
€707,158 2025-03-20
INIBIDORES DE TIROSINACINASES - AXITINIB, CRIZOTINIB E LORLATINIB
PT · 11288734 · Ao abrigo de acordo-qu...
A6 · Low Competition
€326,362 2025-03-17
METILPREDNISOLONA PÓ SOL INJ FR IM IV
PT · 11289132 · Ajuste Direto Regime G...
A6 · Low Competition
€137,594 2025-03-12
2025001845 – Aquisição de medicamentos
PT · 11274877 · Ajuste Direto Regime G...
A6 · Low Competition
€6,000 2025-03-11
RITLECITINIB 50 MG CÁPS
PT · 11289133 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€20,111 2025-02-27
251X000061 - ELRANATAMAB
PT · 11242638 · Contratação excluída II
A6 · Low Competition
€45,798 2025-02-21
Fornecimento de Lorlatinib, Ceftazidima+Avibactam e Pegvisomant ao HSEIT, EPER.
PT · 11227456 · Ajuste Direto Regime G...
A6 · Low Competition
€101,987 2025-02-13
BEAD20250020 - AQUISIÇÃO DE ANTIBACTERIANOS - CEFTAZIDIMA+AVIBACTAM
PT · 11222298 · Ao abrigo de acordo-qu...
A6 · Low Competition
€286,017 2025-02-12
1365/2025 - Convite à apresentação de proposta por ajuste direto para aquisição de T1822 - TOFACITINIB [1 MG/ML;SOL ORAL]
PT · 11221417 · Ajuste Direto Regime G...
A9 · Abnormal Price Reduction A6 · Low Competition
€14,786 2025-02-11
Fornecimento de substância ativa: Tucatinib 150 mg
PT · 11198556 · Ajuste Direto Regime G...
A6 · Low Competition
€105,815 2025-01-29
MEDICAMENTOS LABORATORIOS PFIZER
PT · 11197262 · Ajuste Direto Regime G...
A6 · Low Competition
€190,395 2025-01-24
Aquisição de Medicamentos Exclusivos PFIZER para o ano de 2025
PT · 11243321 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€166,175 2025-01-21
1365/2025 - Convite à apresentação de proposta por ajuste direto para aquisição de T1822 - TOFACITINIB [1 MG/ML;SOL ORAL]
PT · 11283133 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€14,786 2025-01-21
Aquisição do medicamento - Etanercept
PT · 11203747 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€162,784 2024-12-30
2024006222 – Aquisição de medicamentos
PT · 11102556 · Ajuste Direto Regime G...
A6 · Low Competition
€26,856 2024-12-20
Bosutinib 100 mg comp.
PT · 11170908 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€8,212 2024-12-19
CEFTAZIDIMA 2000 MG + AVIBACTAM 500 MG PÓ CONC SOL INJ FR IV
PT · 11105399 · Ao abrigo de acordo-qu...
A6 · Low Competition
€100,399 2024-12-17
Q1/3764/2024 - TOFACITINIB 11MG COMP
PT · 11255228 · Ao abrigo de acordo-qu...
C3 · Missing Mandatory Fields A6 · Low Competition
€28,102 2024-12-11
J1/14/2025 Agregação Urgente – ETANERCEPT - ENBREL Doentes em tratamento – PFIZER
PT · 11261002 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€7,940 2024-12-06
Aquisição de Etanercept - Laboratórios Pfizer
PT · 11067823 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A6 · Low Competition
€17,866 2024-12-05
161001524-AQUISICAO DO MEDICAMENTO PFIZER AUE 202404306
PT · 11639706 · Contratação excluída II
C3 · Missing Mandatory Fields A6 · Low Competition
€23,104 2024-12-05
INIBIDORES DE TIROSINACINASES - PALBOCICLIB
PT · 11049137 · Ao abrigo de acordo-qu...
A6 · Low Competition
€13,391 2024-11-26
Aquisição do medicamento - nirmatrelvir e tucatinib
PT · 11167289 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€11,939 2024-11-25
PALBOCICLIB
PT · 11014552 · Ao abrigo de acordo-qu...
A6 · Low Competition
€18,413 2024-11-08
MEDICAMENTOS PARA A MÁQUINA DE REEMBALAGEM PROUD
PT · 11030220 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€17,103 2024-11-07
Aquisição de ELRANATAMAB 40MG
PT · 11282465 · Contratação excluída II
C3 · Missing Mandatory Fields A6 · Low Competition
€483,072 2024-11-07
BEAD20240484 - AQUISIÇÃO DE TOFACITINIB
PT · 11002688 · Ao abrigo de acordo-qu...
A6 · Low Competition
€15,480 2024-10-31
Fornecimento de MOROCTOCOG alfa ao Hospital de Santo Espírito da Ilha terceira, EPER
PT · 11012419 · Ajuste Direto Regime G...
A9 · Abnormal Price Reduction A6 · Low Competition
€333,711 2024-10-29
Ajuste direto para aquisição de E451 - ETANERCEPT [50 MG/1 ML; SOL. INJ.; CANETA] DOENTES EM TRATAMENTO, E473 - ETANERCEPT [50 MG/1 ML; SOL. INJ.; SERINGA] DOENTES EM TRATAMENTO E S348 - SUNITINIB [50 MG; CÁP/COMP]
PT · 10981488 · Ajuste Direto Regime G...
A9 · Abnormal Price Reduction A6 · Low Competition
€33,377 2024-10-16
Ajuste direto para aquisição de E451 - ETANERCEPT [50 MG/1 ML; SOL. INJ.; CANETA] DOENTES EM TRATAMENTO, E473 - ETANERCEPT [50 MG/1 ML; SOL. INJ.; SERINGA] DOENTES EM TRATAMENTO E S348 - SUNITINIB [50 MG; CÁP/COMP]
PT · 11016945 · Ajuste Direto Regime G...
A2 · Late Publication A9 · Abnormal Price Reduction +1
€33,377 2024-10-15
TUCATINIB 50 MG COMP
PT · 11087635 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€11,290 2024-10-14
EX/2714 /2024- ELRANATAMAB 40MGML INJ 1,9ML SC
PT · 10908055 · Contratação excluída II
A6 · Low Competition
€362,304 2024-09-05
SOMATROPINA
PT · 10864100 · Ao abrigo de acordo-qu...
A6 · Low Competition
€37,951 2024-08-09
ANTIBACTERIANOS - CEFTAZIDIMA + AVIBACTAM
PT · 10858629 · Ao abrigo de acordo-qu...
A6 · Low Competition
€60,239 2024-08-07
AQUISIÇÃO DE MDICAMENTOS PARA AS NECESSIDADES IMEDIATAS DOS DOENTES - DESPACHO 1571-B/2016
PT · 10959107 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€9,131 2024-08-06
INIBIDORES DE TIROSINACINASES - AXITINIB
PT · 10837327 · Ao abrigo de acordo-qu...
A6 · Low Competition
€42,970 2024-07-22
PC 25240043 - Aquisição de Etanercept 50Mg/1Ml Caneta
PT · 10823938 · Ajuste Direto Regime G...
A6 · Low Competition
€88,230 2024-07-17
2024006452 – Aquisição de medicamentos
PT · 10834545 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€34,135 2024-07-12
Aquisição de Tucatinib 150 mg Comp
PT · 10884982 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€26,453 2024-07-05
BEAD20240343 - AQUISIÇÃO DE MEDICAMENTOS PARA SISTEMA NERVOSO CENTRAL - TAFAMIDIS
PT · 10791502 · Ao abrigo de acordo-qu...
A6 · Low Competition
€21,150 2024-06-26
INIBIDORES DE TIROSINACINASES - AXITINIB (EXCLUSIVO) 2024
PT · 10755220 · Ao abrigo de acordo-qu...
A6 · Low Competition
€45,656 2024-06-06
AQUISIÇÃO DE NIRMATRELVIR COMP 150 MG + RITONAVIR COMP 100 MG - EMERGENTE
PT · 10831127 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€28,800 2024-06-03
Fornecimento de substância ativa: Nirmatrelvir+Ritonavir (150mg+100mg)
PT · 11018598 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€270,000 2024-05-29
EAD20240049 - AQUISIÇÃO DE ANTI - HEMORRÁGICOS - NONACOG
PT · 10739317 · Ajuste Direto Regime G...
A9 · Abnormal Price Reduction A6 · Low Competition
€799,938 2024-05-27
AQUISIÇÃO DO MEDICAMENTO ANIDULAFUNGINA [100MG; F/AMP] para a ULSCB E.P.E.
PT · 10763954 · Concurso público
A2 · Late Publication A6 · Low Competition
€21,036 2024-05-23
ANTIBACTERIANOS - CEFTAZIDIMA - 1º SEMESTRE
PT · 10725373 · Ao abrigo de acordo-qu...
A6 · Low Competition
€30,119 2024-05-20
NONACOG ALFA PÓ SOL INJ FR IV
PT · 10985119 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€39,997 2024-05-15
2024003707 – Aquisição de medicamentos
PT · 10717059 · Ajuste Direto Regime G...
A6 · Low Competition
€17,530 2024-05-15
Fornecimento de Lorlatinib ao Hospital de Santo Espírito da Ilha Terceira, EPER
PT · 10804589 · Ajuste Direto Regime G...
A2 · Late Publication A9 · Abnormal Price Reduction +1
€48,666 2024-04-19
Next →
Overview
Total Value Won
€37,032,726,661
Contracts Won
9,615
Score 328155 · CRITICAL RISK
NIF
500162166
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • A.C. [P-f05d]
    Gerente
    since 2022-11-28
  • F.J. [P-b870]
    Gerente
    since 2025-02-27
  • P.A. [P-9563]
    Gerente
    since 2014-06-26
  • P.G. [P-1249]
    Gerente
    since 2008-04-22
  • R.J. [P-516e]
    Gerente
    since 2021-06-22
  • T.S. [P-c179]
    Gerente
    since 2021-06-22
  • P.W. [P-bd21]
    Sócio
    since 2012-08-13
  • P.W. [P-bd21]
    Sócio
    since 2012-08-30
  • P.S. [P-b820]
    Sócio
    since 2012-08-13
  • P.S. [P-b820]
    Sócio
    since 2012-08-30
  • A.P. [P-1479]
    Gerente
    2009-03-04 → 2016-10-06
  • A.P. [P-1479]
    Gerente
    until 2013-10-15
  • A.C. [P-f05d]
    Gerente
    2014-10-28 → 2021-06-22
  • A.P. [P-6d4c]
    Gerente
    2012-10-26 → 2014-11-24
  • B.G. [P-2ebe]
    Gerente
    2023-04-06 → 2025-12-02
  • C.M. [P-2e72]
    Gerente
    2014-06-26 → 2015-07-03
  • C.M. [P-2e72]
    Gerente
    2021-06-22 → 2022-11-28
  • F.J. [P-b870]
    Gerente
    2012-10-26 → 2014-06-26
  • L.R. [P-b234]
    Gerente
    2017-06-07 → 2019-01-24
  • L.F. [P-9705]
    Gerente
    2009-03-04 → 2012-09-24
  • M.D. [P-6765]
    Gerente
    2021-06-22 → 2023-04-06
  • M.M. [P-70e3]
    Gerente
    2009-03-04 → 2015-07-03
  • S.P. [P-a960]
    Gerente
    2019-02-07 → 2021-02-17
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned